Etoposide
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Etoposide
- Etoposide: From Small Cell Lung Cancer to Well-Differentiated Fetal Adenocarcinoma of the Lung
Etoposide: From Small Cell Lung Cancer to Well-Differentiated Fetal Adenocarcinoma of the Lung
One-Sentence Summary
Etoposide is a topoisomerase II inhibitor established as chemotherapy for small cell lung cancer, germ cell tumours and lymphomas. The TxGNN model predicts it may also be effective for well-differentiated fetal adenocarcinoma of the lung (the low-grade epithelial component of pulmonary blastoma), but this is currently supported by 0 clinical trials and only 1 case-report publication, so the evidence base is very thin.
(Note: this evidence pack — candidate ID TW-DB00773-multi — contains 10 TxGNN-predicted indications for Etoposide. This report follows the standard format for the top-ranked prediction; a summary of the other 9 candidates is provided in a supplementary table before the conclusion.)
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Small cell lung cancer, germ cell tumours and lymphomas (per literature evidence, PMID 1984834; no UK marketing authorisation record available in this pack) |
| Predicted New Indication | Well-differentiated fetal adenocarcinoma of the lung |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L4 |
| UK Market Status | Not marketed (per data available in this evidence pack) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Research Question |
Why is This Prediction Reasonable?
Detailed, structured mechanism-of-action data for Etoposide was flagged as a data gap in this evidence pack. Based on information available across the supporting literature and trial records, Etoposide is a topoisomerase II inhibitor (epipodophyllotoxin class): it stabilises the DNA–topoisomerase II cleavage complex, producing double-strand DNA breaks and triggering apoptosis in rapidly dividing cells. This mechanism underlies its long-standing use in small cell lung cancer, germ cell tumours and a wide range of lymphomas and sarcomas, as reflected throughout the trial and publication evidence in this pack (e.g. PMID 1984834, PMID 8070034).
Well-differentiated fetal adenocarcinoma of the lung is the low-grade, low-mitotic-index epithelial component of classic biphasic pulmonary blastoma — a very rare primary lung malignancy that also contains a primitive mesenchymal (sarcomatous) component. Because it is a lung tumour sharing anatomical origin with small cell lung cancer, and because pulmonary blastoma as a whole is a highly proliferative, mixed-histology tumour, there is a plausible mechanistic rationale for cytotoxic, DNA-damaging agents such as Etoposide to have activity here.
However, the supporting evidence is indirect: the single literature record identified (PMID 33107372) describes a case of classic biphasic pulmonary blastoma (the combined epithelial/mesenchymal tumour) treated with nedaplatin plus paclitaxel — not Etoposide specifically, and not the isolated well-differentiated fetal adenocarcinoma subtype. No trial or publication in this pack directly evaluates Etoposide in this specific histological subtype.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33107372 | 2020 | Case Report | The Journal of International Medical Research | Case of classic biphasic pulmonary blastoma (which includes well-differentiated fetal adenocarcinoma as its epithelial component) treated with adjuvant chemotherapy after surgical resection; illustrates the chemosensitivity of this tumour family but does not test Etoposide directly. |
Cytotoxicity
Etoposide is a conventional cytotoxic chemotherapy agent (topoisomerase II inhibitor, epipodophyllotoxin class), as evidenced throughout the trial and literature records in this pack (e.g. its role as the “E” in EPOCH, ICE, VDC/IE and BEACOPP regimens).
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (topoisomerase II inhibitor / epipodophyllotoxin class) |
| Myelosuppression Risk | High — multiple Etoposide-containing regimens in this evidence pack required G-CSF/filgrastim prophylaxis and thrombopoietin-agonist supportive care for febrile neutropenia and thrombocytopenia (e.g. PMID 34962714; NCT01459653) |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Full blood count with differential (given the neutropenia/thrombocytopenia signal in the supporting evidence), plus renal and hepatic function as standard for cytotoxic chemotherapy |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Other Predicted Indications in This Evidence Pack
This evidence pack scored Etoposide against 10 candidate indications. The table below summarises the other 9 for context, since several have materially stronger evidence than the top-ranked prediction above.
| Rank | Disease | TxGNN Score | Evidence Level | Decision Stage | Recommendation |
|---|---|---|---|---|---|
| 2 | Primary pulmonary lymphoma | 99.94% | L2 | S2 | Proceed with Guardrails |
| 3 | Pulmonary blastoma | 99.94% | L4 | S1 | Research Question |
| 4 | Ewing sarcoma | 99.85% | L1 | S3 | Proceed with Guardrails |
| 5 | Botryoid-type embryonal rhabdomyosarcoma of the vagina | 99.80% | L4 | S0 | Hold |
| 6 | Rhabdomyosarcoma (disease) | 99.79% | L1 | S3 | Proceed with Guardrails |
| 7 | Embryonal extrahepatic bile duct rhabdomyosarcoma | 99.76% | L5 | S0 | Hold |
| 8 | Parameningeal embryonal rhabdomyosarcoma | 99.76% | L4 | S1 | Research Question |
| 9 | Extrahepatic bile duct rhabdomyosarcoma | 99.75% | L5 | S0 | Hold |
| 10 | Prostate embryonal rhabdomyosarcoma | 99.74% | L4 | S1 | Research Question |
Note: for rank 4 (Ewing sarcoma) and rank 6 (rhabdomyosarcoma), the evidence pack’s own rationale indicates these reflect confirmation of existing standard-of-care use (Etoposide/Ifosfamide within VDC/IE and related regimens) rather than novel repurposing — the L1 evidence level and multiple Phase 3 RCTs (e.g. PMID 12594313, PMID 36522207, PMID 11846301) support long-established practice rather than a new indication.
Conclusion and Next Steps
Decision: Research Question
Rationale:
- The top-ranked TxGNN prediction (well-differentiated fetal adenocarcinoma of the lung) has a very high model score but only L4 evidence — a single indirect case report, with no trials and no subtype-specific data — so it does not yet support a repurposing decision.
- Two other candidates in this pack (Ewing sarcoma, rhabdomyosarcoma) have L1 evidence, but represent extension/confirmation of Etoposide’s established chemotherapy role rather than new repurposing opportunities.
To proceed, the following is needed:
- UK product labelling/SmPC data (currently blocking — DG001: no warnings, contraindications or DDI data available for safety screening)
- Confirmed mechanism-of-action documentation from DrugBank or equivalent source (DG002)
- A prospective case series or trial specifically evaluating Etoposide-containing regimens in pulmonary blastoma/well-differentiated fetal adenocarcinoma
- Confirmation of current UK marketing authorisation status, since this pack records 0 licences on file
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.